German industry keeps close eye on undue pressure on suppliers:
This article was originally published in Clinica
Executive Summary
Customers seeking discounts from suppliers - in whatever industry sector - is common business practice. German medtech industry association Spectaris notes, however, that pressure from clinics on suppliers to alter price schedules to suit a single - albeit economically important - customer (or group of customers acting as a cartel) effectively contravenes the law on unfair competition (UWG). This is the case if the supplier is constrained by the action of a hospital or clinic in such a way as to prevent it from acting freely. In the era of diagnosis-related groups (DRGs) and tighter budgets, resulting from past and ongoing health finance reforms, the issue is one that industry needs to keep an eye on, feels Spectaris. The association's Harald Hartmann ([email protected]) is currently assessing the extent of the problem.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.